A phase 1/2 study of retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) combination therapy in patients (Pts) with advanced solid tumors.

Authors

Omid Hamid

The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA

Omid Hamid , Martin Gutierrez , Inderjit Mehmi , Monika Dudzisz-Sledz , Paul Edward Hoyle , Wendy Wei , John D. Powderly

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.

First Author: Jayesh Desai

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.

First Author: Thorsten Oliver Goetze

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.

First Author: Mark R. Middleton

insert_chart_outlined

Poster

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update.

First Author: Neil Howard Segal